Veracyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 815
- Market Cap
- -
- Introduction
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Gustave Roussy Launches UMBRELLA Trial: Using Blood-Based Tumor DNA to Revolutionize Cancer Follow-Up Care
Gustave Roussy has initiated UMBRELLA, a groundbreaking phase III trial that personalizes post-treatment cancer monitoring based on minimal residual disease (MRD) detected through blood-based circulating tumor DNA analysis.
Veracyte Expands Decipher Prostate Test to Metastatic Cancer Patients, Offering New Treatment Guidance Tool
Veracyte has launched the Decipher Prostate Metastatic Genomic Classifier, making it the only gene expression test covered by Medicare across all prostate cancer risk levels.
Veracyte's Whole-Genome Sequencing MRD Test Shows Superior Accuracy for Bladder Cancer Detection
New data from the TOMBOLA trial demonstrates Veracyte's whole-genome sequencing-based MRD testing platform detected muscle-invasive bladder cancer with higher specificity than ddPCR-based methods.
Bio-Rad to Acquire Stilla Technologies, Expanding Digital PCR Portfolio
Bio-Rad Laboratories has entered a binding agreement to acquire Stilla Technologies, enhancing its digital PCR capabilities with Stilla's next-generation systems for applications including oncology diagnostics and infectious disease testing.
Advances in Prostate Cancer: From Novel Therapies to Enhanced Diagnostics
Relugolix plus radiotherapy demonstrates safety and efficacy for localized and advanced prostate cancer, offering a potential new treatment approach.
Veracyte's Decipher Test Accurately Predicts Aggressive Prostate Cancer in Black Men
Veracyte's Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer in African American men, according to the VANDAAM trial.